Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORB-021 in Advanced Solid Tumors
NCT06607939Phase 1Recruiting
- Sponsor
- Orionis Biosciences
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ORB-021 in solid tumor, sponsored by Orionis Biosciences. Primary endpoint: Adverse Events at 12 months. Started Nov 2024; status: recruiting.
02
Drugs
ORB-021
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06607939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607939.